Figure 3
WT1-28z and WT1-28z/IL-12 CAR T cells are specific to WT1/HLA-A*02:01. (a and b) WT1-28z or WT1-28z/IL-12 CAR T cells are significantly more toxic than control irrelevant antigen-specific CAR T cells 4H11-28z and 4H11-28z/IL-12 CAR T cells against Set2 and KARPAS-620 in standard 51Cr release assays (representative figures, n=3 for each cell line). WT1-28z significantly more lysed Set2 cells than 4H11-28z CAR T cells at all the effector to target ratios tested (P⩽0.005). WT1-28z/IL-12 significantly more lysed Set2 cells than 4H11-28z/IL-12 CAR T cells at 40:1, 20:1 and 10:1 effector to target ratios tested (P<0.0006). WT1-28z significantly more lysed KARPAS-620 than 4H11-28z CAR T cells at all the effector to target ratios tested (P<0.007). WT1-28z/IL-12 significantly more lysed KARPAS-620 than 4H11-28z/IL-12 CAR T cells at 40:1, 20:1, and 10:1 effector to target ratios tested (P<0.0003). (c) WT1-28z and WT1-28z/IL-12 CAR T cells show no toxicity toward the HLA-A*02:01-positive, WT1-negative cell lines SKLY-16 compared with control 4H11-28z or 4H11-28z/IL-12 CAR T cells in standard 51Cr release assays (n=3). (d) WT1-28z and WT1-28z/IL-12 CAR T cells show no toxicity toward the WT1-positive, HLA-A*02:01-negative cell line HL-60 as compared with control 4H11-28z or 4H11-28z/IL-12 CAR T cells in standard 51Cr release assays (n=3).
